VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
MBOT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
MBOTMicrobot Medical Inc.
$1.90$87M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

MBOT logoMicrobot Medical Inc.(MBOT)Earnings, Financials & Key Ratios

MBOT•NASDAQ
$1.90
Price updated Jul 7, 2026
SectorHealthcareIndustryMedical InstrumentsSub-IndustryRobotic and computer-assisted surgery
AboutMicrobot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.Show more
  • Revenue$0
  • EBITDA-$15M-27.4%
  • Net Income-$13M-14.8%
  • EPS (Diluted)-0.29+60.3%
  • ROE-32.42%+88.6%

MBOT Price & Volume

Microbot Medical Inc. (MBOT) stock price & volume — 10-year historical chart

Loading chart...

Nascent Revenue Fails To Offset Operational Burn

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Critical cash runway depletion

Key Thesis Takeaways

  • Microbot Medical is currently transitioning from a research-focused entity to a commercial-stage firm, yet its financial trajectory remains heavily dependent on dilutive capital raises to sustain operations.
  • While the company reported its first revenue of $105.0K in 2026Q1, the lack of scale and persistent net losses of $3.7M per quarter highlight significant execution risks.
  • Investors should monitor the company's ability to achieve commercial milestones with its Liberty system, as the current cash runway of $3.7M appears insufficient to support long-term development without further financing.

Verdict Logic

the company's cash position has eroded to $3.7 million, which, when measured against a quarterly net loss of $3.7 million, suggests a critical risk of near-term liquidity depletion.

MBOT Growth Metrics

Microbot Medical Inc. (MBOT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-21.75%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM50.95%

Return on Capital

10 Years-102.29%
5 Years-132.68%
3 Years-162.28%
Last Year-36.09%

MBOT Recent Earnings

Microbot Medical Inc. (MBOT) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 13, 2026
Metric
Actual
Est
EPS
$0.05+37.5%
$0.08
Rev
$105,000-76.7%
$450,000
Q2 2026
Mar 26, 2026
Metric
Actual
Est
EPS
$0.04+33.3%
$0.06
Rev
$20,000-82.4%
$113,333
Q4 2025
Nov 12, 2025
Metric
Actual
Est
EPS
$0.07-16.7%
$0.06
Rev
—
$600,000
Q3 2025
Aug 12, 2025
Metric
Actual
Est
EPS
$0.10-25.0%
$0.08
Rev
—
$630,000
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 13, 2026
$0.05vs $0.08+37.5%
$105,000vs $450,000-76.7%
Q2 2026Mar 26, 2026
$0.04vs $0.06+33.3%
$20,000vs $113,333-82.4%
Q4 2025Nov 12, 2025
$0.07vs $0.06-16.7%
—vs $600,000
Q3 2025Aug 12, 2025
$0.10vs $0.08-25.0%
—vs $630,000
Based on last 12 quarters of dataView full earnings history →

Latest MBOT News

Recent stock market news and headlines for Microbot Medical Inc. (MBOT)

GlobeNewsWire·Jun 30, 2026
Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader

HINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into a Letter of Agreement (LOA) with Sanmina Corporation, a leading global integrated manufacturing solutions provider, to manufacture the LIBERTY System, the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures.

GlobeNewsWire·Jun 25, 2026
Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System

HINGHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has won the Innovative Start-Up Award from Surgical Robotics Technology (SRT), which recognizes companies with outstanding technological and commercial progress through highly innovative, groundbreaking technologies with the potential for broad healthcare impact.1 SRT, a leading platform for surgical robotics news, together with QNX, recognizes outstanding organizations, individuals, and technologies across the surgical robotics sector.

GlobeNewsWire·Jun 23, 2026
Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System

Leading academic center with multi-hospital and multi-state health system deepens Company's footprint in the Northeast U.S. The Company now has multiple accounts and hospitals that have adopted the LIBERTY System across seven states in the U.S. HINGHAM, Mass., June 23, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that a globally recognized academic center headquartered in Pennsylvania is the first in the state to adopt the LIBERTY System, allowing the Company to further expand its presence in the Northeast U.S., joining other health systems in New York City and Boston that have also adopted the LIBERTY System.

GlobeNewsWire·Jun 16, 2026
Microbot Medical® Enters Into an Agreement to Expand Access for America's Veteran and Military Patient Populations

HINGHAM, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into an agreement with Lovell® Government Services to serve federal healthcare systems, such as those administered by the Veterans Health Administration (VHA), a division of the U.S. Department of Veteran Affairs, the Military Health System (MHS), which is run by the U.S. Department of Defense, and the U.S. Indian Health Service (IHS).

Peers Comparison

Key metrics vs top competitors for Microbot Medical Inc. (MBOT)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
MBOT logoMBOTMicrobot Medical Inc.Current
$1.90$86.58M-6.55——-32.42%—
SSYS logoSSYSStratasys Ltd.
$8.21$707.48M-6.41-3.73%-21.01%-13.44%—
RBOT logoRBOTVicarious Surgical Inc.
$0.16$1.02M-0.02——-333.19%—
TRVI logoTRVITrevi Therapeutics, Inc.
$19.50$2.77B-67.24——-24.53%—
ISRG logoISRGIntuitive Surgical, Inc.
$427.30$151.33B54.2920.51%28.15%16.89%—
NVCR logoNVCRNovoCure Limited
$17.72$2.02B-14.528.28%-25.66%-50.82%—

Compare MBOT vs Peers

Microbot Medical Inc. (MBOT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs SSYS

Most directly comparable listed peer for MBOT.

Scale Benchmark

vs ABT

Larger-name benchmark to compare MBOT against a more recognizable public peer.

Peer Set

Compare Top 5

vs SSYS, RBOT, TRVI, ISRG

MBOT SEC Filings & Documents

Microbot Medical Inc. (MBOT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 15, 2026·SEC

Material company update

May 14, 2026·SEC

Material company update

May 5, 2026·SEC

10-K Annual Reports

1
FY 2026

Mar 26, 2026·SEC

10-Q Quarterly Reports

3
FY 2026

May 13, 2026·SEC

FY 2025

Nov 12, 2025·SEC

FY 2025

Aug 12, 2025·SEC

Get notified when MBOT posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

MBOT Frequently Asked Questions

Microbot Medical Inc. (MBOT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Microbot Medical Inc.'s revenue?

Microbot Medical Inc. (MBOT) reported $0.1M in revenue for fiscal year 2025. This represents a 99% decrease from $7.1M in 1996.

Is MBOT profitable?

Microbot Medical Inc. (MBOT) reported a net loss of $14.2M for fiscal year 2025.

Dividend & Returns
What is MBOT's return on equity?

Microbot Medical Inc. (MBOT) has a return on equity (ROE) of -32.4%. Negative ROE indicates the company is unprofitable.

What is Microbot Medical Inc.'s free cash flow?

Microbot Medical Inc. (MBOT) had negative free cash flow of $15.4M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in MBOT back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →